We are live on ! Find out more
INDV icon

Indivior Pharmaceuticals

259 hedge funds and large institutions have $4.36B invested in Indivior Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 90 funds opening new positions, 84 increasing their positions, 67 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,820% more call options, than puts

Call options by funds: $78M | Put options by funds: $4.07M

246% more first-time investments, than exits

New positions opened: 90 | Existing positions closed: 26

63% more capital invested

Capital invested by funds: $2.68B → $4.36B (+$1.68B)

31% more funds holding

Funds holding: 198259 (+61)

25% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 67

0% more funds holding in top 10

Funds holding in top 10: 1010 (0)

Holders
259
Holders Change
+61
Holders Change %
+30.81%
% of All Funds
3.15%
Holding in Top 10
10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.12%
New
90
Increased
84
Reduced
67
Closed
26
Calls
$78M
Puts
$4.07M
Net Calls
+$74M
Net Calls Change
+$18.1M
Name Holding Trade Value Shares
Change
Change in
Stake
Two Sigma Investments
76
Two Sigma Investments
New York
$4.13M -$942K -30,857 -21%
T. Rowe Price Associates
77
T. Rowe Price Associates
Maryland
$4.12M +$878K +28,746 +33%
NA
78
Navellier & Associates
Nevada
$4.12M +$3.51M +114,904 New
BNP Paribas Asset Management
79
BNP Paribas Asset Management
France
$3.96M +$3.37M +110,348 New
RSCM
80
Rock Springs Capital Management
Maryland
$3.77M +$3.21M +105,100 New
Franklin Resources
81
Franklin Resources
California
$3.68M +$1.36M +44,614 +77%
Man Group
82
Man Group
United Kingdom
$3.61M -$1.46M -47,679 -32%
SCM
83
Soleus Capital Management
Connecticut
$3.59M -$41.7M -1,366,000 -93%
SCM
84
Stonepine Capital Management
Oregon
$3.59M
CEI
85
Clark Estates Inc
New York
$3.31M -$1.87M -61,300 -40%
Citigroup
86
Citigroup
New York
$3.3M +$1.68M +55,064 +149%
New York State Teachers Retirement System (NYSTRS)
87
New York State Teachers Retirement System (NYSTRS)
New York
$3.06M +$2.6M +85,251 New
California State Teachers Retirement System (CalSTRS)
88
California State Teachers Retirement System (CalSTRS)
California
$3.05M -$302K -9,894 -10%
Massachusetts Financial Services
89
Massachusetts Financial Services
Massachusetts
$2.98M +$2.54M +83,135 New
OAM
90
OP Asset Management
$2.76M +$2.35M +76,846 New
AIC
91
AWM Investment Company
New York
$2.71M
PC
92
Panoramic Capital
California
$2.69M +$1.28M +41,892 +126%
JCIA
93
Jackson Creek Investment Advisors
Colorado
$2.6M +$351K +11,493 +19%
CP
94
CenterBook Partners
Connecticut
$2.44M -$1.26M -41,380 -38%
MIM
95
MetLife Investment Management
New Jersey
$2.41M -$174K -5,703 -8%
TI
96
Trexquant Investment
Connecticut
$2.4M -$1.38M -45,359 -40%
SOADOR
97
State of Alaska Department of Revenue
Alaska
$2.28M +$1.94M +63,538 New
Raymond James Financial
98
Raymond James Financial
Florida
$2.18M +$368K +12,053 +25%
NCM
99
Nearwater Capital Markets
Ireland
$2.15M
American Century Companies
100
American Century Companies
Missouri
$2.15M +$1.05M +34,378 +135%

INDV Hedge Fund Activity: Q4 2025 in Review

259 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Indivior Pharmaceuticals (INDV) for Q4 2025, worth a combined $4.36B — up 63% from $2.68B a quarter earlier.

Buyers outnumbered sellers: 90 funds opened new INDV positions and 26 closed out — a net gain of 64 holders — while 84 added to existing stakes and 67 trimmed.

The largest buyer was BlackRock, adding an estimated $290M. The largest seller was Oaktree Capital Management, cutting an estimated $7.65B.

  • 259 institutional investors held Indivior Pharmaceuticals (INDV) as of Q4 2025, up from 198 in Q3 2025.
  • Funds reported $4.36B of Indivior Pharmaceuticals stock for Q4 2025, up 63% quarter-over-quarter.
  • 90 funds opened new Indivior Pharmaceuticals positions in Q4 2025 and 26 closed out, a net change of +64 holders.
  • The largest Indivior Pharmaceuticals buyer in Q4 2025 was BlackRock, an estimated $290M added.
  • The largest Indivior Pharmaceuticals seller in Q4 2025 was Oaktree Capital Management, an estimated $7.65B sold.

Based on aggregated 13F filings for Q4 2025.